Scholarlink

Background <p>Acute myeloid leukemia (AML) remains a therapeutically challenging hematological malignancy with high relapse rates, especially in patients harboring mutations in the <i>FMS-like tyrosine kinase 3</i> (<i>FLT3</i>) gene. FLT3, a receptor tyrosine kinase involved in hematopoietic cell proliferation and survival, is frequently mutated or overexpressed in AML, contributing to leukemic proliferation and poor prognosis. Although FLT3 inhibitors have demonstrated clinical benefit, resistance often develops, underscoring the need for alternative treatment strategies.</p> Methods <p>In this study, we developed and evaluated allogeneic anti-FLT3 CAR T cells engineered by CRISPR/Cas9-mediated targeted integration into the <i>T cell receptor α constant</i> (<i>TRAC</i>) locus (TRAC-CAR T). This approach enables CAR expression under the endogenous <i>TRAC</i> promoter while simultaneously disrupting native TCR expression, thereby allowing the use of allogeneic T cells with reduced risk of graft-versus-host disease.</p> Results <p>TRAC-CAR T cells demonstrated efficient disruption of TCRαβ expression, robust surface CAR expression, and superior integration efficiency compared to safe harbor <i>AAVS1</i>-targeted and lentivirally transduced CAR T cells (LV-CAR T). Functionally, TRAC-CAR T cells exhibited potent and selective cytotoxicity against FLT3-positive AML cell lines in vitro, achieving comparable killing relative to LV-CAR T cells. In a xenograft AML mouse model, TRAC-CAR T cells effectively reduced leukemia burden and prolonged mouse survival, with efficacy matching that of LV-CAR T cells. Notably, TRAC-CAR T cells exhibited reduced exhaustion marker expression.</p> Conclusions <p>Together, these results highlight <i>TRAC</i>-integrated anti-FLT3 CAR T cells as a promising off-the-shelf immunotherapy candidate, combining precise gene editing, efficient manufacturing, and potent anti-leukemic activity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Maya G. Noer,
  • Kimmie B. Christensen,
  • Nanna S. Mikkelsen,
  • Sigrid Fu Skjelbostad,
  • Frederik H. Rothemejer,
  • Thomas Wittenborn,
  • Simon Fammé,
  • Kasper Mikkelsen,
  • Torben Barington,
  • Martin K. Thomsen,
  • Mike B. Barnkob,
  • Bjarne K. Møller,
  • Rasmus O. Bak

摘要

Background

Acute myeloid leukemia (AML) remains a therapeutically challenging hematological malignancy with high relapse rates, especially in patients harboring mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. FLT3, a receptor tyrosine kinase involved in hematopoietic cell proliferation and survival, is frequently mutated or overexpressed in AML, contributing to leukemic proliferation and poor prognosis. Although FLT3 inhibitors have demonstrated clinical benefit, resistance often develops, underscoring the need for alternative treatment strategies.

Methods

In this study, we developed and evaluated allogeneic anti-FLT3 CAR T cells engineered by CRISPR/Cas9-mediated targeted integration into the T cell receptor α constant (TRAC) locus (TRAC-CAR T). This approach enables CAR expression under the endogenous TRAC promoter while simultaneously disrupting native TCR expression, thereby allowing the use of allogeneic T cells with reduced risk of graft-versus-host disease.

Results

TRAC-CAR T cells demonstrated efficient disruption of TCRαβ expression, robust surface CAR expression, and superior integration efficiency compared to safe harbor AAVS1-targeted and lentivirally transduced CAR T cells (LV-CAR T). Functionally, TRAC-CAR T cells exhibited potent and selective cytotoxicity against FLT3-positive AML cell lines in vitro, achieving comparable killing relative to LV-CAR T cells. In a xenograft AML mouse model, TRAC-CAR T cells effectively reduced leukemia burden and prolonged mouse survival, with efficacy matching that of LV-CAR T cells. Notably, TRAC-CAR T cells exhibited reduced exhaustion marker expression.

Conclusions

Together, these results highlight TRAC-integrated anti-FLT3 CAR T cells as a promising off-the-shelf immunotherapy candidate, combining precise gene editing, efficient manufacturing, and potent anti-leukemic activity.